TGTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
TG THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$53.30−0.67 (-1.24%)
Close on Oct 19, 2026
- Market cap
- $8.38B
- P/E (TTM)
- 19.5
- Dividend yield
- –
TG THERAPEUTICS, INC. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product [Member] | $785.53M | $688.58M | $606.93M | $525.16M | $449.14M | $382.90M | $313.73M | $249.52M | $191.29M | $134.73M | $92.01M | $48.91M | 98.2% | +74.9% |
| License [Member] | $14.00M | $11.77M | $9.36M | $6.74M | $4.93M | $3.49M | $15.28M | $15.27M | $155.44M | $154.61M | $141.66M | $140.86M | 1.8% | +184.3% |
| Royalty [Member] | – | – | – | – | – | $1.37M | $801.00K | $412.00K | $183.00K | $33.00K | $0 | – | – | – |
| Other Revenue [Member] | – | – | – | – | – | $1.97M | $1.82M | $2.21M | $2.60M | $1.92M | $1.50M | – | – | – |
| License Revenue [Member] | – | – | – | $5.94M | $4.13M | $2.69M | $152.00K | $1.53M | $140.99M | $140.15M | $140.15M | – | – | – |
| Milestone [Member] | – | – | – | – | – | $0 | $12.50M | $12.50M | $12.50M | $12.50M | $0 | – | – | – |
By region
From the segment and revenue-disaggregation notes of Tg Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.